141 423

Cited 9 times in

A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention

DC Field Value Language
dc.contributor.author고영국-
dc.contributor.author김병극-
dc.date.accessioned2014-12-20T16:49:45Z-
dc.date.available2014-12-20T16:49:45Z-
dc.date.issued2011-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93456-
dc.description.abstractPURPOSE: It is unknown whether cilostazol pretreatment reduces postprocedural myonecrosis (PPMN). Cilostazol pretreatment reduces PPMN after percutaneous coronary intervention (PCI). MATERIALS AND METHODS: A total of 120 patients with stable angina scheduled for elective PCI were randomly assigned to a 7-day pretreatment with Cilostazol (200 mg/day) or to a control group. Creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured at baseline and at 6 and 24 hours after PCI. The primary end-point was the occurrence of PPMN, defined as any CK-MB elevation above the upper normal limit (UNL). Aspirin and clopidogrel were co-administered for 7 days before PCI, and resistance to these agents was then assayed using the VerifyNow System. RESULTS: There was no difference in baseline characteristics between the final analyzable cilostazol (n=54) and the control group (n=56). Despite a significantly greater % inhibition of clopidogrel in the cilostazol group (39±23% versus 25±22%, p=0.003), the incidence of PPMN was similar between the cilostazol group (24%) and the control group (25%, p=1.000). The rate of CK-MB elevation at ≥3 times UNL was also similar between the two groups (6% versus 5%, p=0.583). The incidence of cTnI increase over the UNL or to 3 times the UNL was not different between the two groups. There was no significant difference in terms of the rate of adverse events during follow- up, although the cilostazol group showed a tendency to have a slightly higher incidence of entry site hematoma. CONCLUSION: This trial demonstrated that adjunctive cilostazol pretreatment might not significantly reduce PPMN after elective PCI in patients with stable angina.-
dc.description.statementOfResponsibilityopen-
dc.format.extent717~726-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAngina, Stable/drug therapy-
dc.subject.MESHAngina, Stable/enzymology-
dc.subject.MESHAngina, Stable/therapy-
dc.subject.MESHAngioplasty, Balloon, Coronary/adverse effects*-
dc.subject.MESHCreatine Kinase, MB Form/blood-
dc.subject.MESHFemale-
dc.subject.MESHHeart Injuries/etiology-
dc.subject.MESHHeart Injuries/prevention & control-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMyocardium/pathology-
dc.subject.MESHNecrosis-
dc.subject.MESHPhosphodiesterase 3 Inhibitors/administration & dosage*-
dc.subject.MESHProspective Studies-
dc.subject.MESHTetrazoles/administration & dosage*-
dc.titleA randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorSeung Jin Oh-
dc.contributor.googleauthorSe-Jung Yoon-
dc.contributor.googleauthorDong Woon Jeon-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorJoo Young Yang-
dc.identifier.doi10.3349/ymj.2011.52.5.717-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00127-
dc.contributor.localIdA00493-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid21786434-
dc.subject.keywordCoronary disease-
dc.subject.keywordmyocardial infarction-
dc.subject.keywordstents-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.alternativeNameKim, Byeong Keuk-
dc.contributor.affiliatedAuthorKo, Young Guk-
dc.contributor.affiliatedAuthorKim, Byeong Keuk-
dc.rights.accessRightsfree-
dc.citation.volume52-
dc.citation.number5-
dc.citation.startPage717-
dc.citation.endPage726-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.52(5) : 717-726, 2011-
dc.identifier.rimsid28246-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.